Brief: Shenzhen Hepalink Pharmaceutical to invest in Canada's Resverlogix Corp
13/10/2017 11:48
Oct 13 (Reuters) - Shenzhen Hepalink Pharmaceutical Co Ltd
002399.SZ
* Says it plans to invest up to C$87 million ($69.75
million) in Canada's Resverlogix Corp RVX.TO
Source text in Chinese: http://bit.ly/2i9ZrGw
Further company coverage: 002399.SZ
($1 = 1.2473 Canadian dollars)
(Reporting by Hong Kong newsroom)
((hongkong.newsroom@thomsonreuters.com; (852) 2843-6441;
Reuters Messaging: chyenyee.lee.reuters.com@reuters.net))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment